Evidence map›Paper›PMID 33275949›Full record

SynthesisThe Lancet. Global health2021

Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study.

GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study

Erratum issued 6 registry-linked trialsOpen access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in The Lancet. Global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 6 registered trials, which are not on this map. Cited by 1,549 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,549citing papers in PubMed, 9 pooled it
188.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05201378 completednot on this map

Deep Sclerectomy vs Xen in Solo Procedure: Comparative Study, Efficacy and Safety Profile

TypeobservationalSponsorFondation Hôpital Saint-JosephRan2021 to 2022Enrolled282ConditionsGlaucoma
NCT05457348 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Effect of Single Incision Versus Three Planned Incision to Reduce Pre-operative Astigmatism After Phacoemulsification.

TypeinterventionalSponsorSuleman Roshan Medical CollegeRan2022 to 2023Enrolled160ConditionsAstigmatism of Both EyesArmsPlanned incisions during phacoemulsification
NCT06000280 nacompletednot on this map

Evaluation of Macular Thickness in Patients With Glaucoma in Use of Topical Prostaglandin Analogue Undergoing Trabeculectomy With Mitomycin C

TypeinterventionalSponsorUniversidade Federal de GoiasRan2021 to 2023Enrolled37ConditionsGlaucomaArmsTrabeculectomy surgery
NCT06076785 unknown statusnot on this mapstarted 2023, after this paper: background citation

Impact of ODYSight in the Management of patientS With imparairEd Visual acuitY (ODYSSEY).

TypeobservationalSponsorTilak HealthcareRan2023 to 2024Enrolled300ConditionsImpaired Visual AcuityArmsOdySight
NCT07135570 recruitingnot on this mapstarted 2025, after this paper: background citation

Stop Blindness in Coastal Bangladesh: Testing the Effectiveness of Community-Based, Artificial Intelligence-Assisted Eye Disease Screening in Coastal Bangladesh

TypeobservationalSponsorData Yakka, Inc.Ran2025 to 2026Enrolled20,000ConditionsGlaucoma, Diabetic Retinopathy (DR), Hypertensive Retinopathy, CataractArmsMultimodal Screening for Eye Disease, cataract surgery
NCT07640256 phase4completednot on this mapstarted 2023, after this paper: background citation

Safety and Efficacy of Peribulbar Anesthesia for Pain Management in Patients With Proliferative Diabetic Retinopathy During Panretinal Photocoagulation

TypeinterventionalSponsorAsociación para Evitar la Ceguera en MéxicoRan2023 to 2024Enrolled50ConditionsProliferative Diabetic RetinopathyArmsPeribulbar anesthesia with 0.5% bupivacaine and 2% lidocaine, Tetracaine 5% drops
3 · Its place in the literature

Who cites it

1,549 citing papers in PubMed, 9 syntheses or guidelines pooled it, 2,888 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Optimizing Mydriasis in Cataract Surgery: Efficacy and Safety of Intracameral Regimen vs Topical Cyclopentolate in RayOne EMV Implantation.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Article
  18. Article
  19. Article
  20. Article

1,489 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 20 institutions in 34 countries.

GBD 2019 Blindness and Vision Impairment Collaborators
Vision Loss Expert Group of the Global Burden of Disease Study
University of Washington · USImperial College London · GBIran University of Medical Sciences · IRTehran University of Medical Sciences · IRVita-Salute San Raffaele University · ITBahir Dar University · ETCairo University · EGDatta Meghe Institute of Higher Education and Research · INHarvard University Press · USHeidelberg University · DEShahid Beheshti University of Medical Sciences · IRUniversidade do Porto · PTUniversity of Gondar · ETUniversity of Michigan · USAdigrat University · ETAksum University · ETAll India Institute of Medical Sciences · INAnglia Ruskin University · GBBabol University of Medical Sciences · IRBaku State University · AZ

Funding

University of Utah, Core Vision Research GrantP30EY014800 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Bryan William Jones · 2005 to 2026
$14.6M
Endothelial Transmigration in Neovascular Age-related Macular DegenerationR01EY017011 · NEI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HARTNETT, MARY ELIZABETH RUTH · 2007 to 2025
$7.7M
Mechanisms of Angiogenesis of Retinopathy of PrematurityR01EY015130 · NEI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mary Elizabeth Ruth Hartnett · 2005 to 2026
$7.6M
Deconstructing and Modeling the Single Cell Architecture of the Age-Related Macular Degeneration Retina and RPE/ChoroidR01EY031209 · NEI · UNIVERSITY OF PENNSYLVANIA · PI DEANGELIS, MARGARET M, LI, MINGYAO · 2020 to 2024
$2.7M
Department of Health HTA 09/104/40NEI NIH HHS P30 EY014800NEI NIH HHS R01 EY015130NEI NIH HHS R01 EY017011NEI NIH HHS R01 EY031209
6 · The paper itself

Abstract

backgroundMany causes of vision impairment can be prevented or treated. With an ageing global population, the demands for eye health services are increasing. We estimated the prevalence and relative contribution of avoidable causes of blindness and vision impairment globally from 1990 to 2020. We aimed to compare the results with the World Health Assembly Global Action Plan (WHA GAP) target of a 25% global reduction from 2010 to 2019 in avoidable vision impairment, defined as cataract and undercorrected refractive error.

methodsWe did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We fitted hierarchical models to estimate prevalence (with 95% uncertainty intervals [UIs]) of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness (<3/60 or less than 10° visual field around central fixation) by cause, age, region, and year. Because of data sparsity at younger ages, our analysis focused on adults aged 50 years and older.

findingsGlobal crude prevalence of avoidable vision impairment and blindness in adults aged 50 years and older did not change between 2010 and 2019 (percentage change -0·2% [95% UI -1·5 to 1·0]; 2019 prevalence 9·58 cases per 1000 people [95% IU 8·51 to 10·8], 2010 prevalence 96·0 cases per 1000 people [86·0 to 107·0]). Age-standardised prevalence of avoidable blindness decreased by -15·4% [-16·8 to -14·3], while avoidable MSVI showed no change (0·5% [-0·8 to 1·6]). However, the number of cases increased for both avoidable blindness (10·8% [8·9 to 12·4]) and MSVI (31·5% [30·0 to 33·1]). The leading global causes of blindness in those aged 50 years and older in 2020 were cataract (15·2 million cases [9% IU 12·7-18·0]), followed by glaucoma (3·6 million cases [2·8-4·4]), undercorrected refractive error (2·3 million cases [1·8-2·8]), age-related macular degeneration (1·8 million cases [1·3-2·4]), and diabetic retinopathy (0·86 million cases [0·59-1·23]). Leading causes of MSVI were undercorrected refractive error (86·1 million cases [74·2-101·0]) and cataract (78·8 million cases [67·2-91·4]).

interpretationResults suggest eye care services contributed to the observed reduction of age-standardised rates of avoidable blindness but not of MSVI, and that the target in an ageing global population was not reached.

fundingBrien Holden Vision Institute, Fondation Théa, The Fred Hollows Foundation, Bill & Melinda Gates Foundation, Lions Clubs International Foundation, Sightsavers International, and University of Heidelberg.

Indexed as

Global Burden of DiseaseGlobal HealthVisual AcuityAgedAged, 80 and overBlindnessCataractEye DiseasesFemaleGlaucomaHumansMacular DegenerationMaleMiddle AgedRefractive ErrorsVision Disorders

Identifiers

PMID33275949
PMCPMC7820391
OpenAlexW3110220146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.